Parkinson Disease
暂无分享,去创建一个
[1] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[2] D. Brooks,et al. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. , 2020, Brain : a journal of neurology.
[3] V. Gradinaru,et al. Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice , 2020, Nature Neuroscience.
[4] Nikhil Panicker,et al. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease , 2019, Neuron.
[5] H. McBride,et al. Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1−/− mice , 2019, Nature.
[6] W. V. van IJcken,et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes , 2019, Nature Neuroscience.
[7] S. Mantri,et al. State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease , 2019, npj Parkinson's Disease.
[8] S. Purdy,et al. Gavel Club for people with aphasia: communication confidence and quality of communication life , 2019 .
[9] Yoshihiro Kokubo,et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.
[10] H. Cai,et al. Parkin and PINK1 mitigate STING-induced inflammation , 2018, Nature.
[11] H. Chong,et al. Individual Therapeutic Singing Program for Vocal Quality and Depression in Parkinson’s Disease , 2018, Journal of movement disorders.
[12] Xiang Gao,et al. Non-motor features of Parkinson’s disease in a nested case–control study of US men , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[13] J. Kulisevsky,et al. Update in therapeutic strategies for Parkinson's disease , 2018, Current opinion in neurology.
[14] T. Postmus. Genetics of Parkinson's disease , 2018 .
[15] Avril Lee,et al. Medicine Administration in People with Parkinson’s Disease in New Zealand: An Interprofessional, Stakeholder-Driven Online Survey , 2018, Dysphagia.
[16] G. Oyama,et al. Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation , 2018, BMJ Case Reports.
[17] P. Videira,et al. Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease , 2018, Front. Neurosci..
[18] Sung-Rae Cho,et al. Relationship Between Swallowing Function and Maximum Phonation Time in Patients With Parkinsonism , 2018, Annals of rehabilitation medicine.
[19] Z. Mari,et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease , 2018, Nature Medicine.
[20] P. Warnke,et al. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[21] Toshiyuki Yamamoto,et al. Dysphagia Causes Symptom Fluctuations after Oral L-DOPA Treatment in a Patient with Parkinson Disease , 2018, Case Reports in Neurology.
[22] R. Pahwa,et al. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients. , 2018, Neurodegenerative disease management.
[23] Mariana Aurora Cansino-Torres,et al. Allergy to Carbidopa , 2018, Clinical neuropharmacology.
[24] P. Hobson,et al. Mortality and quality of death certification in a cohort of patients with Parkinson’s disease and matched controls in North Wales, UK at 18 years: a community-based cohort study , 2018, BMJ Open.
[25] Anna Miles,et al. Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study , 2017, Journal of the Neurological Sciences.
[26] C. Barlow,et al. Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson's disease. , 2017, Parkinsonism & related disorders.
[27] J. Assmus,et al. Glitazone use associated with reduced risk of Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.
[28] L. Segall. The effect of group singing on the voice and swallow function of healthy, sedentary, older adults: A pilot study , 2017 .
[29] Satoshi Morita,et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model , 2017, Nature.
[30] J. C. Vest,et al. Lumbee traditional medicine: Neuroprotective activities of medicinal plants used to treat Parkinson's disease-related symptoms. , 2017, Journal of ethnopharmacology.
[31] N. Hattori,et al. Clinical evaluation of ropinirole controlled-release formulation at 18-24 mg/day in Japanese patients with Parkinson's disease. , 2017, Parkinsonism & related disorders.
[32] C. Marini,et al. Obstructive sleep apnea syndrome in Parkinson's disease and other parkinsonisms. , 2017, Functional neurology.
[33] Annelise Ayres,et al. The Impact of Deep Brain Stimulation on the Quality of Life and Swallowing in Individuals with Parkinson's Disease , 2017, International Archives of Otorhinolaryngology.
[34] Nir Giladi,et al. A randomized trial of a low‐dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.
[35] Sanghee Moon,et al. Qigong Exercise May Reduce Serum TNF-α Levels and Improve Sleep in People with Parkinson’s Disease: A Pilot Study , 2017, Medicines.
[36] E. Stegemöller,et al. Therapeutic singing as an early intervention for swallowing in persons with Parkinson's disease. , 2017, Complementary therapies in medicine.
[37] C. Sapienza,et al. Effects of singing on voice, respiratory control and quality of life in persons with Parkinson’s disease , 2017, Disability and rehabilitation.
[38] L. Vécsei,et al. Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy , 2017, Drug design, development and therapy.
[39] N. Chen,et al. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation. , 2017, Toxicology letters.
[40] T. Warnecke,et al. Esophageal dysfunction in different stages of Parkinson's disease , 2017, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[41] O. Tysnes,et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease , 2016, Nature Communications.
[42] N. Osada,et al. Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-test. , 2016, Parkinsonism & related disorders.
[43] Aline Aparecida Foppa,et al. Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study , 2016, Neurology and Therapy.
[44] S. Purdy,et al. Choral singing therapy following stroke or Parkinson’s disease: an exploration of participants’ experiences , 2016, Disability and rehabilitation.
[45] B. Kremer,et al. Voice‐ and swallow‐related quality of life in idiopathic Parkinson's disease , 2016, The Laryngoscope.
[46] T. Warnecke,et al. Dysphagia in Parkinson’s Disease , 2016, Dysphagia.
[47] D. Novakovic,et al. Adult obstructive sleep apnoea and the larynx , 2015, Current opinion in otolaryngology & head and neck surgery.
[48] D. Maltête,et al. Impact of deep brain stimulation on pharyngo‐esophageal motility: a randomized cross‐over study , 2015, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[49] H. Sawada,et al. Impact of Aspiration Pneumonia on the Clinical Course of Progressive Supranuclear Palsy: A Retrospective Cohort Study , 2015, PloS one.
[50] Krupa Patel. Optimising medication for Parkinson's disease patients with dysphagia. , 2015, British journal of community nursing.
[51] Nicole C. Swann,et al. Therapeutic deep brain stimulation reduces cortical phase-amplitude coupling in Parkinson's disease , 2015, Nature Neuroscience.
[52] S. Daniels,et al. Dysphagia Management in Stroke Rehabilitation , 2014, Current Physical Medicine and Rehabilitation Reports.
[53] B. Kremer,et al. Treatment effects for dysphagia in Parkinson's disease: a systematic review. , 2014, Parkinsonism & related disorders.
[54] Richard D. Jones,et al. Skill training for swallowing rehabilitation in patients with Parkinson's disease. , 2014, Archives of physical medicine and rehabilitation.
[55] R. Soose,et al. What is the role of the larynx in adult obstructive sleep apnea? , 2014, The Laryngoscope.
[56] Tejas Sankar,et al. Deep brain stimulation for Parkinson's disease and other movement disorders. , 2013, Current opinion in neurology.
[57] H. Shill,et al. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. , 2013, Journal of neuropathology and experimental neurology.
[58] T. Cunha-Oliveira,et al. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. , 2012, Free radical biology & medicine.
[59] T. Dawson,et al. Animal models of Parkinson's disease: vertebrate genetics. , 2012, Cold Spring Harbor perspectives in medicine.
[60] F. Baker,et al. The effect of group music therapy on mood, speech, and singing in individuals with Parkinson's disease--a feasibility study. , 2012, Journal of music therapy.
[61] D. Surmeier,et al. Physiological phenotype and vulnerability in Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.
[62] A. Brice,et al. What genetics tells us about the causes and mechanisms of Parkinson's disease. , 2011, Physiological reviews.
[63] K. Tieu,et al. A guide to neurotoxic animal models of Parkinson's disease. , 2011, Cold Spring Harbor perspectives in medicine.
[64] Graham K Kerr,et al. Prevalence of malnutrition in Parkinson's disease: a systematic review. , 2011, Nutrition reviews.
[65] C. Goetz. The history of Parkinson's disease: early clinical descriptions and neurological therapies. , 2011, Cold Spring Harbor perspectives in medicine.
[66] Shimon Sapir,et al. Intensive voice treatment in Parkinson’s disease: Lee Silverman Voice Treatment , 2011, Expert review of neurotherapeutics.
[67] Miguel Ángel Martínez,et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.
[68] M. Okun,et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST , 2010, Neurology.
[69] D. Yang,et al. The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[70] Roy W Jones,et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.
[71] T. Südhof,et al. α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro , 2010, Science.
[72] Anatol C. Kreitzer,et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.
[73] E. Ringelstein,et al. Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy , 2010, Movement disorders : official journal of the Movement Disorder Society.
[74] H. Reichmann. Clinical Criteria for the Diagnosis of Parkinson’s Disease , 2010, Neurodegenerative Diseases.
[75] T. Schallert,et al. Targeted exercise therapy for voice and swallow in persons with Parkinson's disease , 2010, Brain Research.
[76] S. Mandel,et al. Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy , 2010, EPMA Journal.
[77] M. Farrer,et al. Missing pieces in the Parkinson's disease puzzle , 2010, Nature Medicine.
[78] Christy L Ludlow,et al. Electrical neuromuscular stimulation in dysphagia: current status , 2010, Current opinion in otolaryngology & head and neck surgery.
[79] Marc Cruts,et al. Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update , 2010, Human mutation.
[80] M. Cookson,et al. Parkinson's disease: insights from pathways. , 2010, Human molecular genetics.
[81] A. Abeliovich. Parkinson's disease: Mitochondrial damage control , 2010, Nature.
[82] J. Ostrem,et al. OVERVIEW OF COMMON MOVEMENT DISORDERS , 2010, Continuum.
[83] Atsushi Tanaka,et al. PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.
[84] A. Lang,et al. Hereditary parkinsonism: Parkinson disease look‐alikes—An algorithm for clinicians to “PARK” genes and beyond , 2009, Movement disorders : official journal of the Movement Disorder Society.
[85] M. Okun,et al. The relationship between quality of life and swallowing in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[86] M. Okun,et al. Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease. , 2009, Chest.
[87] A. Zapf,et al. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias , 2009, European journal of neurology.
[88] M. Dafotakis,et al. Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis , 2009, Journal of Clinical Neuroscience.
[89] Grant D. Huang,et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. , 2009, JAMA.
[90] P. Haggard. Human volition: towards a neuroscience of will , 2008, Nature Reviews Neuroscience.
[91] S. Jick,et al. Use of antihypertensives and the risk of Parkinson disease , 2008, Neurology.
[92] Hitoshi Takahashi,et al. α-Synuclein pathology in the neostriatum in Parkinson’s disease , 2008, Acta Neuropathologica.
[93] C. Tanner,et al. Association of olfactory dysfunction with risk for future Parkinson's disease , 2008, Annals of neurology.
[94] J. Nutt,et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk , 2008, Movement disorders : official journal of the Movement Disorder Society.
[95] M. Weisskopf,et al. Plasma urate and risk of Parkinson's disease. , 2007, American journal of epidemiology.
[96] M. Kringelbach,et al. Translational principles of deep brain stimulation , 2007, Nature Reviews Neuroscience.
[97] Jennifer L. Spielman,et al. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. , 2007, Journal of speech, language, and hearing research : JSLHR.
[98] L. Skipper,et al. Pathogenic mutations in Parkinson disease , 2007, Human mutation.
[99] D. James Surmeier,et al. ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease , 2007, Nature.
[100] D. Nicholl,et al. Genetics of Parkinson’s disease and parkinsonism , 2007, Expert review of neurotherapeutics.
[101] Di Chen,et al. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[102] L. Ramig,et al. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. , 2006, Seminars in speech and language.
[103] L. Ramig,et al. The Lee Silverman Voice Treatment® for voice, speech and other orofacial disorders in patients with Parkinson’s disease , 2006 .
[104] M. Farrer. Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.
[105] G. Bing,et al. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease , 2006, Journal of Neuroinflammation.
[106] N. Wood,et al. Expanding insights of mitochondrial dysfunction in Parkinson's disease , 2006, Nature Reviews Neuroscience.
[107] N. Wood,et al. Molecular genetic pathways in Parkinson's disease: a review. , 2005, Clinical science.
[108] Nir Giladi,et al. A Group Intervention Model for Speech and Communication Skills in Patients With Parkinson's Disease , 2005 .
[109] Yue Huang,et al. Genetic contributions to Parkinson's disease , 2004, Brain Research Reviews.
[110] M. Vila,et al. Genetic clues to the pathogenesis of Parkinson's disease , 2004, Nature Medicine.
[111] A. Schober,et al. Genes, proteins, and neurotoxins involved in Parkinson’s disease , 2004, Progress in Neurobiology.
[112] L. Ramig,et al. Parkinson's disease: speech and voice disorders and their treatment with the Lee Silverman Voice Treatment. , 2004, Seminars in speech and language.
[113] Tatiana Foroud,et al. Genetics of Parkinson disease , 2004, Genetics in Medicine.
[114] Lorene M Nelson,et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. , 2003, American journal of epidemiology.
[115] H. Braak,et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.
[116] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[117] Jeri Logemann,et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT®): a pilot study , 2002, INTERSPEECH.
[118] S. Countryman,et al. Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up , 2001 .
[119] C. Tanner,et al. Frequency of bowel movements and the future risk of Parkinson’s disease , 2001, Neurology.
[120] J Q Trojanowski,et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.
[121] S. Countryman,et al. Changes in vocal loudness following intensive voice treatment (LSVT®) in individuals with Parkinson's disease: A comparison with untreated patients and normal age‐matched controls , 2001, Movement disorders : official journal of the Movement Disorder Society.
[122] Heidi Phillips,et al. Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.
[123] E. Quigley,et al. Cricopharyngeal dysfunction in Parkinson's disease: Role in dysphagia and response to myotomy , 1996, Movement disorders : official journal of the Movement Disorder Society.
[124] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[125] O. Hornykiewicz,et al. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.
[126] Jung-Hoon Lee,et al. Effects of neuromuscular electrical stimulation in patients with Parkinson's disease and dysphagia: A randomized, single-blind, placebo-controlled trial. , 2018, NeuroRehabilitation.
[127] A. Wehr,et al. Effects of a formal exercise program on Parkinson's disease: a pilot study using a delayed start design. , 2014, Parkinsonism & related disorders.
[128] M. Okun,et al. Detraining outcomes with expiratory muscle strength training in Parkinson disease. , 2014, Journal of rehabilitation research and development.
[129] J. Girault. Signaling in striatal neurons: the phosphoproteins of reward, addiction, and dyskinesia. , 2012, Progress in molecular biology and translational science.
[130] W. Schmidt,et al. Vaccination for Parkinson's disease. , 2012, Parkinsonism & related disorders.
[131] Christine Klein,et al. Genetics of Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.
[132] David J Brooks,et al. Parkinson's disease: diagnosis. , 2012, Parkinsonism & related disorders.
[133] J. Stockman. Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .
[134] R. Youle,et al. Mechanisms of mitophagy , 2010, Nature Reviews Molecular Cell Biology.
[135] R. Burgoyne,et al. Chaperoning the SNAREs: a role in preventing neurodegeneration? , 2010, Nature Cell Biology.
[136] A. Singleton. Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. , 2005, Trends in neurosciences.
[137] M. Vila,et al. Neurological diseases: Targeting programmed cell death in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.
[138] J. Ghika. [Genetics of parkinsonism]. , 2000, Revue medicale de la Suisse romande.
[139] M. C. Kagel,et al. Pharyngo-Esophageal Dysphagia in Parkinson's Disease , 1997, Dysphagia.